slides · global inventory
Title
Component collection for the active corpus filters, with each row opening the slide detail view.
Matching slides 303,780
Current window 226,411-226,440
Pages 10,126
Rows per page 30
Component
226,411-226,440 of 303,780
57
The slide uses a log-linear plot to demonstrate drug clearance over time.Immatics | Investor Presentation Deck | 75 slides · Immatics
Pitch deck Investor relations 1 hit
59
Immatics | Investor Presentation Deck | 75 slidesImmatics | Investor Presentation Deck | 75 slides · Immatics
Pitch deck Investor relations 1 hit
67
Immatics | Investor Presentation Deck | 75 slidesImmatics | Investor Presentation Deck | 75 slides · Immatics
Pitch deck Investor relations 1 hit
68
The slide uses a grid layout with headshots and professional titles for 9 executives.Immatics | Investor Presentation Deck | 75 slides · Immatics
Pitch deck Investor relations Beat · Team1 hit
69
The slide highlights the trans-atlantic nature of the organization with specific operational focus areas per site.Immatics | Investor Presentation Deck | 75 slides · Immatics
Pitch deck Investor relations Beat · Team1 hit
70
Immatics | Investor Presentation Deck | 75 slidesImmatics | Investor Presentation Deck | 75 slides · Immatics
Pitch deck Investor relations 1 hit
71
Includes waterfall plot and spider plot for RECIST 1.1 response metrics.Immatics | Investor Presentation Deck | 75 slides · Immatics
Pitch deck Investor relations 1 hit
73
Data cut-off Sep 30, 2023. N=21 patients.Immatics | Investor Presentation Deck | 75 slides · Immatics
Pitch deck Investor relations 1 hit
75
Immatics | Investor Presentation Deck | 75 slidesImmatics | Investor Presentation Deck | 75 slides · Immatics
Pitch deck Investor relations 1 hit
02
Immix Biopharma | Investor Presentation Deck | 64 slidesImmix Biopharma | Investor Presentation Deck | 64 slides · Immix Biopharma
Pitch deck Investor relations 1 hit
03
Immix Biopharma | Investor Presentation Deck | 64 slidesImmix Biopharma | Investor Presentation Deck | 64 slides · Immix Biopharma
Pitch deck Investor relations Loop · Golden Circle1 hit
04
The slide uses a structured grid layout to categorize team members into three distinct groups: Leadership, Board of Directors, and Scientific Advisory Board.Immix Biopharma | Investor Presentation Deck | 64 slides · Immix Biopharma
Pitch deck Investor relations 1 hit
05
The slide uses a cause-and-effect structure to map platform capabilities to strategic outcomes.Immix Biopharma | Investor Presentation Deck | 64 slides · Immix Biopharma
Pitch deck Investor relations Beat · Solution1 hit
07
Includes a cartoon illustration of a cell/virus character.Immix Biopharma | Investor Presentation Deck | 64 slides · Immix Biopharma
Pitch deck Investor relations Beat · ProblemLoop · Cost Of Inaction1 hit
08
The slide uses a structural diagram to highlight the specific modifications (COBRA Binder) that differentiate NXC-201 from the reference therapy.Immix Biopharma | Investor Presentation Deck | 64 slides · Immix Biopharma
Pitch deck Investor relations Beat · Solution1 hit
09
The slide uses a diagram to map specific protein domains to their functional benefits.Immix Biopharma | Investor Presentation Deck | 64 slides · Immix Biopharma
Pitch deck Investor relations Beat · Solution1 hit
10
The slide uses authority-citation to validate the mechanism of ITAM modification and degradation.Immix Biopharma | Investor Presentation Deck | 64 slides · Immix Biopharma
Pitch deck Investor relations 1 hit
11
The slide uses a combination of bar charts for preclinical cytokine release and a table for clinical outcomes to demonstrate the competitive advantage of NXC-201.Immix Biopharma | Investor Presentation Deck | 64 slides · Immix Biopharma
Pitch deck Investor relations 1 hit
12
The slide compares HSL (Heavy-chain-led) vs LSH (Light-chain-led) configurations, demonstrating superior performance for HSL.Immix Biopharma | Investor Presentation Deck | 64 slides · Immix Biopharma
Pitch deck Investor relations 1 hit
13
Includes a cartoon mascot at the bottom.Immix Biopharma | Investor Presentation Deck | 64 slides · Immix Biopharma
Pitch deck Investor relations 1 hit
14
The slide explicitly notes that this is a cross-trial comparison and not a head-to-head study.Immix Biopharma | Investor Presentation Deck | 64 slides · Immix Biopharma
Pitch deck Investor relations 1 hit
15
The slide uses a biological structural diagram to illustrate the proprietary nature of the COBRA binding domain compared to standard CAR-T constructs.Immix Biopharma | Investor Presentation Deck | 64 slides · Immix Biopharma
Pitch deck Investor relations 1 hit
17
The slide uses a multi-panel line chart to compare clinical outcomes across three different therapies.Immix Biopharma | Investor Presentation Deck | 64 slides · Immix Biopharma
Pitch deck Investor relations 1 hit
18
The chart demonstrates the mechanism of action: rapid cell expansion followed by clearance within 30 days, correlating with disease marker reduction.Immix Biopharma | Investor Presentation Deck | 64 slides · Immix Biopharma
Pitch deck Investor relations Beat · Traction1 hit
20
The slide uses a grouped bar chart format to compare clinical outcomes across different therapeutic agents.Immix Biopharma | Investor Presentation Deck | 64 slides · Immix Biopharma
Pitch deck Investor relations Beat · Traction1 hit
21
The slide uses a table to contrast treatment efficacy and patient growth across disease stages.Immix Biopharma | Investor Presentation Deck | 64 slides · Immix Biopharma
Pitch deck Investor relations Beat · Traction1 hit
22
The slide explicitly notes that these are cross-trial comparisons and not head-to-head results.Immix Biopharma | Investor Presentation Deck | 64 slides · Immix Biopharma
Pitch deck Investor relations Beat · Traction1 hit
24
Uses a visual icon-grid to represent market expansion.Immix Biopharma | Investor Presentation Deck | 64 slides · Immix Biopharma
Pitch deck Investor relations Beat · Market Sizing1 hit
25
Includes detailed clinical trial citations in the footer.Immix Biopharma | Investor Presentation Deck | 64 slides · Immix Biopharma
Pitch deck Investor relations Beat · Market Sizing1 hit
26
The slide uses a two-column layout to separate milestones by drug candidate.Immix Biopharma | Investor Presentation Deck | 64 slides · Immix Biopharma
Pitch deck Investor relations Beat · Market Sizing1 hit